<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Recent research has shown that congenital nonhemolytic low grade <z:hpo ids='HP_0002904'>hyperbilirubinemias</z:hpo> in patients with <z:e sem="disease" ids="C0017551" disease_type="Disease or Syndrome" abbrv="">Gilbert's syndrome</z:e> (GS) are linked to mutations in the TATA box upstream of the <z:chebi fb="0" ids="16704">uridine</z:chebi> 5'-diphosphoglucose glucuronosyltransferase (UGT1A1) gene leading to an impaired <z:chebi fb="0" ids="16990">bilirubin</z:chebi> glucuronidation </plain></SENT>
<SENT sid="1" pm="."><plain>In routine clinical practice GS patients can, however, only be suspected by exclusion of other causes of <z:hpo ids='HP_0002904'>hyperbilirubinemia</z:hpo> or substantial <z:e sem="disease" ids="C0023895" disease_type="Disease or Syndrome" abbrv="">liver diseases</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>We developed a new, sensitive, convenient, and economic polymerase chain reaction (PCR) method for the rapid and reliable identification of gene polymorphisms in the TATA box of the UGT1A1 gene using fluorescence resonance energy transfer (FRET) </plain></SENT>
<SENT sid="3" pm="."><plain>With this procedure the genotype frequency in a cohort of 266 unrelated individuals from Southern Germany was investigated and the allelic distribution for individual genotypes was 43:45:12 for the (TA)(6)<z:chebi fb="2" ids="32497">TAA</z:chebi>:(TA)(6)<z:chebi fb="2" ids="32497">TAA</z:chebi>/(TA)(7)<z:chebi fb="2" ids="32497">TAA</z:chebi>:(TA)(7)<z:chebi fb="2" ids="32497">TAA</z:chebi> alleles, respectively </plain></SENT>
<SENT sid="4" pm="."><plain>The homozygous (TA)(7)<z:chebi fb="2" ids="32497">TAA</z:chebi> genotype was strongly associated with suspected Gilbert's patients and its prevalence in our cohort of 266 Southern German individuals was 12.4% </plain></SENT>
<SENT sid="5" pm="."><plain>In this cohort total mean serum <z:chebi fb="0" ids="16990">bilirubin</z:chebi> levels ranged from 5 micromol/L (<z:mp ids='MP_0002169'>wild-type</z:mp> 6/6 allele) to 57 micromol/L serum total <z:chebi fb="0" ids="16990">bilirubin</z:chebi> (mutant 7/7 homozygous allele) </plain></SENT>
<SENT sid="6" pm="."><plain>Median (interquartile range) serum total <z:chebi fb="0" ids="16990">bilirubin</z:chebi> levels were 12 (6) and 21 (13) for the homozygous <z:mp ids='MP_0002169'>wild-type</z:mp> and mutant allele, respectively </plain></SENT>
<SENT sid="7" pm="."><plain>Our assay enables individual guidance for dose adjustment in suspected GS patients undergoing long-term drug therapies, especially if glucuronidation via UGT1A1 is a major metabolic pathway </plain></SENT>
</text></document>